DiscoverI AM BIOHow Biotechs Survive the Valley of Death (REDUX)
How Biotechs Survive the Valley of Death (REDUX)

How Biotechs Survive the Valley of Death (REDUX)

Update: 2024-01-10
Share

Description

For biotech companies, the valley of death describes the difficult path from initial discovery to FDA approval and commercialization. It's a treacherous journey—one that even promising innovations often don't complete. Adequate funding, regulatory hurdles and the immense complexity of the biotech landscape are among the never-ending challenges faced by early stage biotechs. In this episode we talk with two biotech executives about what it’s like to struggle and survive in this rough-and-tumble industry.  

Follow us on LinkedIn, X, Facebook and Instagram

Visit us at https://www.bio.org/

Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

How Biotechs Survive the Valley of Death (REDUX)

How Biotechs Survive the Valley of Death (REDUX)

Nancy Simonian CEO Syros Pharmaceuticals, Daphne Zohar Founder & CEO PureTech Health